Literature DB >> 30302624

Real World Evidence: Time for a Switch?

Rachel E Sobel1, Andrew Bate2, Robert F Reynolds1.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 30302624     DOI： 10.1007/s40264-018-0739-y

Source DB:  PubMed          Journal:  Drug Saf        ISSN： 0114-5916            Impact factor:   5.606


× No keyword cloud information.
  13 in total

1.  The FDA's sentinel initiative--A comprehensive approach to medical product surveillance.

Authors:  R Ball; M Robb; S A Anderson; G Dal Pan
Journal:  Clin Pharmacol Ther       Date:  2016-01-12       Impact factor: 6.875

2.  ACOG Committee Opinion No. 375: Brand versus generic oral contraceptives.

Authors: 
Journal:  Obstet Gynecol       Date:  2007-08       Impact factor: 7.661

3.  Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs.

Authors:  J Bohn; C Kortepeter; M Muñoz; K Simms; S Montenegro; G Dal Pan
Journal:  Clin Pharmacol Ther       Date:  2015-04-03       Impact factor: 6.875

4.  Evaluation of Switching Patterns in FDA's Sentinel System: A New Tool to Assess Generic Drugs.

Authors:  Joshua J Gagne; Jennifer R Popovic; Michael Nguyen; Sukhminder K Sandhu; Patty Greene; Rima Izem; Wenlei Jiang; Zhong Wang; Yueqin Zhao; Andrew B Petrone; Anita K Wagner; Sarah K Dutcher
Journal:  Drug Saf       Date:  2018-12       Impact factor: 5.606

5.  Evaluation of FDA safety-related drug label changes in 2010.

Authors:  Jean Lester; George A Neyarapally; Earlene Lipowski; Cheryl Fossum Graham; Marni Hall; Gerald Dal Pan
Journal:  Pharmacoepidemiol Drug Saf       Date:  2013-01-02       Impact factor: 2.890

6.  Comparison of Outcomes Following a Switch From a Brand to an Authorized Versus Independent Generic Drug.

Authors:  R A Hansen; J Qian; R L Berg; J G Linneman; E Seoane-Vazquez; S Dutcher; S Raofi; C D Page; P L Peissig
Journal:  Clin Pharmacol Ther       Date:  2017-10-10       Impact factor: 6.875

7.  Comparative effectiveness of generic and brand-name statins on patient outcomes: a cohort study.

Authors:  Joshua J Gagne; Niteesh K Choudhry; Aaron S Kesselheim; Jennifer M Polinski; David Hutchins; Olga S Matlin; Troyen A Brennan; Jerry Avorn; William H Shrank
Journal:  Ann Intern Med       Date:  2014-09-16       Impact factor: 25.391

Review 8.  Adherence and health care costs.

Authors:  Aurel O Iuga; Maura J McGuire
Journal:  Risk Manag Healthc Policy       Date:  2014-02-20

9.  Medication changes after switching from CONCERTA® brand methylphenidate HCl to a generic long-acting formulation: A retrospective database study.

Authors:  Daniel Fife; M Soledad Cepeda; Alan Baseman; Henry Richards; Peter Hu; H Lynn Starr; Anthony G Sena
Journal:  PLoS One       Date:  2018-02-28       Impact factor: 3.240

10.  Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study.

Authors:  Rishi J Desai; Ameet Sarpatwari; Sara Dejene; Nazleen F Khan; Joyce Lii; James R Rogers; Sarah K Dutcher; Saeid Raofi; Justin Bohn; John Connolly; Michael A Fischer; Aaron S Kesselheim; Joshua J Gagne
Journal:  BMJ       Date:  2018-04-03
View more
  1 in total

Review 1.  Review of Clinical Research Informatics.

Authors:  Anthony Solomonides
Journal:  Yearb Med Inform       Date:  2020-08-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.